Medication info
DynaB Slow Release Tablet (Metformin Hydrochloride)

DynaB Slow Release Tablet (Metformin Hydrochloride)

Prescription medicationTabletOral
Ingredient · strength
Metformin Hydrochloride›500mg / 1 tablet
Manufacturer / importer
Korea Hutech Pharmaceuticals Co., Ltd.
Appearance
White, double-convex, rectangular slow release tablet
Packaging
30 tablets/bottle, 300 tablets/bottle
Approval status
Active

MFDS item code 201502947 · Approved 2015.05.15 · Insurance code 649102730

Summary

Main use
Treatment of type 2 diabetes mellitus in adults inadequately controlled by diet and exercise
Who takes it
Adults
Adult dose
The dose should be determined individually based on drug efficacy and tolerability, and should not exceed the recommended maximum daily dose. - The usual initial dose is 500mg of metformin hydrochloride extended-release tablets once daily with the evening meal. - Blood glucose levels should be measured after one week and the dose adjusted. Gastrointestinal adverse reactions may improve with gradual dose increases. The maximum dose is 2000mg per day. - When increasing the dose, increase it by 500mg each week, up to a maximum of 2000mg per day, taken with the evening meal. If glycemic control is not achieved with a maximum of 2000mg once daily, consider administering 1000mg 2 times daily; both doses should be taken with meals. - For patients already being treated with metformin tablets, the initial dose of this formulation is the same as the daily dose of immediate-release metformin tablets. Switching to this formulation is not recommended for patients taking more than 2000mg per day of immediate-release metformin tablets. - When initiating treatment and adjusting the dose, fasting blood glucose should be measured to assess the response to this drug and determine the minimum effective dose. Glycated hemoglobin levels should be measured approximately every 3 months. - The goal of treatment with this drug, when administered as monotherapy or in combination with a sulfonylurea or insulin, is to reduce fasting blood glucose and glycated hemoglobin levels to normal or near-normal levels using the minimum effective dose. Patients with renal impairment This drug may be used in patients with moderate renal impairment at stage 3a (creatinine clearance [CrCl] 45≤~ <60ml/min or glomerular filtration rate (GFR) 45≤~ <60 mL/min/1.73 m2), provided they do not have other conditions that may increase the risk of lactic acidosis, with the following dose adjustment: - The initial dose is 500mg or 750mg once daily. The maximum daily dose is 1000mg. Renal function should be monitored closely every 3- 6 months. If creatinine clearance or glomerular filtration rate decreases to less than 45ml/min or 45ml/min/1.73m2, respectively, this drug must be discontinued immediately.

Ingredients

Manufacturer
Korea Hutech Pharmaceuticals Co., Ltd.

Efficacy & effects

Treatment of type 2 diabetes mellitus in adults inadequately controlled by diet and exercise

  • Poor blood sugar control
  • type 2 diabetes
View approved original text

This medication is used for the treatment of adult patients with type 2 diabetes, especially those who are overweight, when blood sugar control is insufficient with diet and exercise alone. It is effective as monotherapy, but if necessary, it can be used in combination with other oral hypoglycemic agents or insulin to assist in blood sugar management. This helps to stabilize blood sugar levels and achieve positive effects in diabetes treatment.

How to take

Adult dose

The dose should be determined individually based on drug efficacy and tolerability, and should not exceed the recommended maximum daily dose. - The usual initial dose is 500mg of metformin hydrochloride extended-release tablets once daily with the evening meal. - Blood glucose levels should be measured after one week and the dose adjusted. Gastrointestinal adverse reactions may improve with gradual dose increases. The maximum dose is 2000mg per day. - When increasing the dose, increase it by 500mg each week, up to a maximum of 2000mg per day, taken with the evening meal. If glycemic control is not achieved with a maximum of 2000mg once daily, consider administering 1000mg 2 times daily; both doses should be taken with meals. - For patients already being treated with metformin tablets, the initial dose of this formulation is the same as the daily dose of immediate-release metformin tablets. Switching to this formulation is not recommended for patients taking more than 2000mg per day of immediate-release metformin tablets. - When initiating treatment and adjusting the dose, fasting blood glucose should be measured to assess the response to this drug and determine the minimum effective dose. Glycated hemoglobin levels should be measured approximately every 3 months. - The goal of treatment with this drug, when administered as monotherapy or in combination with a sulfonylurea or insulin, is to reduce fasting blood glucose and glycated hemoglobin levels to normal or near-normal levels using the minimum effective dose. Patients with renal impairment This drug may be used in patients with moderate renal impairment at stage 3a (creatinine clearance [CrCl] 45≤~ <60ml/min or glomerular filtration rate (GFR) 45≤~ <60 mL/min/1.73 m2), provided they do not have other conditions that may increase the risk of lactic acidosis, with the following dose adjustment: - The initial dose is 500mg or 750mg once daily. The maximum daily dose is 1000mg. Renal function should be monitored closely every 3- 6 months. If creatinine clearance or glomerular filtration rate decreases to less than 45ml/min or 45ml/min/1.73m2, respectively, this drug must be discontinued immediately.

Precautions

This medication can rarely cause a serious condition known as lactic acidosis, which can be fatal. Caution is advised when using this drug with other diabetes treatments as severe hypoglycemia can occur. Do not use this medication in patients with moderate to severe renal dysfunction, dehydration, severe infection, acute heart problems, and other such conditions. Especially, the administration of this drug should be suspended before and after tests involving acute heart failure or contrast agents, and should only be resumed after normal kidney function is confirmed. Patients who are allergic to this drug's ingredients, those with type 1 diabetes, or those with severe metabolic acidosis should also not take this medication. Caution is needed for patients with severe infections, serious trauma, before and after surgery, malnutrition, liver dysfunction, severe gastrointestinal disorders, or excessive alcohol consumption; in such cases, temporary cessation of the drug may be warranted. Regular monitoring of kidney function is required during the use of this medication, and drug administration should be discontinued immediately if kidney function deteriorates. Additionally, blood sugar levels should be monitored continuously, and if symptoms of hypoglycemia or suspected lactic acidosis appear, medical personnel should be notified immediately. Gastrointestinal disturbances may frequently occur during initial treatment but typically improve over time. This medication can interact with other drugs, so it is important to inform medical personnel of any other medications being taken. During pregnancy, it should be used with caution for the health of the fetus and mother; during breastfeeding, it is advisable to avoid this medication. Elderly patients are at a higher risk for renal function decline, necessitating dosage adjustments and regular kidney function inspections. In case of overdose, hypoglycemia is unlikely, but the drug can accumulate in the body, requiring immediate treatment. This medication is not recommended for children as its safety and efficacy have not been established. The tablets should not be chewed or crushed, but taken whole, and do not worry if the tablet shell is excreted after administration. When taking this medication, avoid alcohol consumption and maintain regular meals, exercise, and consistent monitoring of blood sugar and kidney function.

Side effects

  • Severe lactic acidosis
  • severe hypoglycemia
  • vitamin B12 deficiency
  • taste impairment
  • nausea
  • vomiting
  • diarrhea
  • abdominal pain
  • loss of appetite
  • erythema
Show 3 more
  • itching
  • urticaria
  • rash

Not everyone experiences these, and they can vary from person to person.

Storage

This medication may be sensitive to air or moisture, so it must be stored in a tightly closed container. It should be kept at a safe temperature between 1 to 30 degrees Celsius, which is not too hot or too cold.

Appearance and packaging

Appearance

White, double-convex, rectangular slow release tablet

Package unit

30 tablets/bottle, 300 tablets/bottle

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.